

# 2026 Independent Medical Education Request for Proposal

Issue Date: April 21, 2026

The *Independent Medical Education team at Genentech, a member of the Roche Group*, invites accredited educational providers to submit applications for independent, certified medical education grants subject to the terms described below. This Request for Proposal (RFP) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific or educational needs exist and funding is available.

**Purpose:** As part of Genentech’s scientific mission, Genentech supports grants for independent medical education that aim to improve patient care by focusing on the improved application of knowledge, competence, and performance among healthcare professionals. This mission is achieved by supporting quality independent education that addresses evidence-based, bona fide educational gaps in accordance with the ACCME, AMA, PhRMA Code, OIG and FDA guidance.

**Notification:** Genentech RFPs are made available through our online Genentech Funding Request System (gFRS) site (<http://funding.gene.com>). In addition, an email is distributed to all registered gFRS users who have previously applied for support of an independent education activity. The email distribution list may not always be up to date. Please periodically check our online Genentech Funding Request System (gFRS) site (<http://funding.gene.com>) to stay informed on current funding priorities. *There have been no predetermined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.*

## Terms and Conditions

1. All grant applications received in response to this RFP will be reviewed in accordance with all Genentech policies and policy guidelines. (Please refer to the publicly available criteria on <http://funding.gene.com>)
2. This RFP does not commit Genentech to award a grant or pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this RFP.
4. For compliance reasons, and in fairness to all providers, all communications about this RFP must come exclusively to Genentech’s department of Medical Education and Research Grants. Failure to comply will automatically disqualify providers.
5. Failure to follow the instructions within this RFP may result in a denial.

## Eligibility Criteria:

- U.S.-based education provider
- Registered account in gFRS
- Accredited to provide CME/CE and in good standing (e.g. ACCME, ANCC, ACPE, etc.)
- Educational initiatives must be U.S.-based only

| Submission Directions | Application Process   | Deadlines    |
|-----------------------|---|--------------|
| Step 1                | Providers who meet the eligibility criteria and are interested in submitting a response to this RFP will have 4 weeks to complete a full application. Please include “ <b>2026 DLBCL RFP</b> ” in the title of your program | May 15, 2026 |

|        |  |                       |
|--------|--|-----------------------|
| Step 2 | After 3 weeks, respective Genentech Medical Education Managers will review and provide notification of final decisions via email | Week of June 15, 2026 |
|--------|--|-----------------------|

**Additional Considerations**

Provider(s) who are awarded grants are encouraged but not required to:

1. Demonstrate key findings via outcomes analysis and report the extent to which the education met the stated objectives and other key findings.
2. Describe how learners demonstrated competence, performance, or patient outcomes improvement as a result of the educational activity.
3. Summarize (through written analysis) the provider’s understanding and interpretation of the outcomes data and identify any persistent educational gaps, unanticipated barriers and/or activity/outcomes limitations.

**1 Currently Available RFP Focus Area:**

| <b>Focus</b>   | <b>Opportunity</b>   |
|--|--|
| <p><b>Therapeutic Area:</b><br/>Hematology</p> <p><b>Disease:</b><br/>Diffuse Large B-Cell Lymphoma</p> <p><b>Learning Audience:</b><br/>Community<br/>Heme-Oncs,<br/>Nurses/Nurse Practitioners,<br/>Pharmacists</p> <p><b>Support Available:</b><br/><br/>Up to \$150k</p> <p>Knowledge- and Competence-based Regional and Local Education</p> | <p>Diffuse Large B-Cell Lymphoma (DLBCL) is a heterogeneous disease where approximately 40% of patients will either be relapsed or refractory (R/R) after initial therapy. While curative-intent options like autologous stem cell transplant (ASCT) and CAR-T therapy are standard for eligible patients, significant barriers limit access for the majority of the patient population.</p> <p>There remains a significant medical care gap for R/R DLBCL patients who are not candidates for cellular therapies or lack access to them. In addition, standard chemoimmunotherapy (CIT) in R/R DLBCL is often associated with limited long-term efficacy and significant treatment burden. As the R/R DLBCL landscape evolves with the emergence of novel T-cell engaging therapies and targeted combinations, it is important for healthcare professionals in the community to understand how to incorporate these regimens into practice.</p> <p>Genentech seeks to support independent medical education that addresses these clinical and logistical gaps, to enhance the knowledge and competence of community-based teams regarding options to treat R/R DLBCL, including the operationalization of novel therapeutic classes and the optimization of management and care coordination within local practice environments.</p> <p>References:</p> <ol style="list-style-type: none"> <li>1. Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. <i>N Engl J Med.</i> 2021;384(9):842-858.</li> <li>2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). B-Cell Lymphomas. Version 2.2025.</li> <li>3. Mahmoudjafari Z, et al. Seamless Navigation of Bispecific Therapies: Optimizing Management and Outpatient Access With a Focus on Coordination. <i>J Adv Pract Oncol.</i> 2024;15(8):741-753.</li> </ol> |